本研究團隊近年來已成功使用手持式原型機檢測出多種心血管疾病蛋白質生物指標。急性心肌梗塞最重要的蛋白質生物指標之一為心肌肌鈣蛋白-I (cTnI)。然而，若要成功發展可即時診斷之cTnI感測器，讓病患得以長期且經常性地進行追蹤心血管疾病，檢測儀器必須要具有良好的靈敏度、穩定度及再現性。
本研究中，在不改變電路與晶片設計的情況下，先藉由調整金氧半場效電晶體的閘極電壓和汲極電壓，來了解此感測器之穩定度機制。此外，不同的抗體濃度之蛋白質標的物檢測，對感測器的靈敏度及解析度有所影響。因此採用三種不同濃度的cTnI抗體進行檢測。最後比較4%BSA、血清及全血環境下的cTnI檢測結果。本實驗成果可作為將來優化手持式生醫感測器重要的依據。

In recent years, our research team has successfully detected a variety of protein biomarkers for cardiovascular diseases (CVDs). One of the most important protein biomarkers for myocardial infarction in the blood is cardiac troponin I (cTnI). However, the final goal of development of the cTnI FET sensor should allow patients to track CVDs regularly. Therefore, the device must have better sensitivity, stability and reproducibility. In this study, without changing the design of the circuit and chip, the control of voltage condition and antibody concentration were applied to confirm the stability mechanism of the cTnI FET sensor. The stability was defined by the standard deviation (SD) of source-drain current. From the results, the gm was found as an important factor for determining the SD and sensitivity. The comparison results of 4%BSA, serum and whole blood could prove the ability of the sensor. The results of this experiment can be used as an significant basis for optimizing hand-held biomedical sensors in the future.

ABSTRACT I
摘要 II
目錄 III
圖片目錄 IV
表格目錄 VI
第一章 緒論 1
1.1. 研究動機與背景介紹 1
1.2. 研究目標 2
第二章 文獻探討 3
2.1. 心血管疾病生物指標—心肌肌鈣蛋白I 3
2.2. 場效電晶體生醫感測器的發展 6
2.3. 場效電晶體感測器中的雜訊來源及穩定度 9
第三章 研究方法 14
3.1. 實驗方法 14
3.2. 研究變項之定義與測量 20
3.3. 數據蒐集方法及分析程序 22
第四章 實驗結果與討論 27
4.1. 金氧半場效電晶體之特性量測結果 27
4.2. 電晶體感測器於不同環境檢測之結果 30
4.3. 不同濃度抗體之抗體電訊號量測結果 35
4.4. 不同濃度抗體之光學訊號量測結果 37
4.5. 不同濃度抗體長時間穩定度量測結果 39
4.6. 蛋白質標的物量測結果 41
4.7. CTNI於血清及全血中量測結果 53
第五章 結論 60
第六章 參考文獻 61

[1] 2000. Cardiovascular disease. Nat. Biotech. 18, pp. IT15–IT17.
[2] E.J. Benjamin, M.J. Blaha, S.E. Chiuve, et al. Heart disease and stroke statistics—2017 update: a report From the American Heart Association, Circulation (2017)
[3] 2016. 8. Cardiovascular Disease and Risk Management. Diabetes Care 39(Supplement 1), pp. S60–S71 (rticle prepared by American diabetes association).
[4] G.A. Roth, M.D. Huffman, A.E. Moran, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013, Circulation, 132 (17) (2015), pp. 1667-1678
[5] S. Yusuf, S. Rangarajan, K. Teo, S. Islam, et al. Cardiovascular risk and events in 17 Low-, middle-, and high-income countries, N. Engl. J. Med., 371 (9) (2014), pp. 818-827
[6] J.T. Lee, K.D. Lawson, Y. Wan, A. et al. Are cardiovascular disease risk assessment and management programes cost effective? A systematic review of the evidence,Prev. Med., 99 (2017), pp. 49-57
[7] J.A. de Lemos, D.M. Lloyd-Jones. “Multiple biomarker panels for cardiovascular risk assessment”, N. Engl. J. Med., 358 (20) (2008), pp. 2172-2174
[8] V.L. RogerEpidemiology of myocardial infarction, Med. Clin. North Am., 91 (4) (2007)
[9] Neumann, J.; Sörensen, N.; Schwemer, T.; et al. JAMA Cardiology 2016, 1, 397−404.
[10] Mythili, S.; Malathi, N. Biomed. Rep. 2015, 3, 743−748.
[11] L. Babuin, A.S. Jaffe, Troponin: the biomarker of choice for the detection of cardiac injury, CMAJ: Can. Med. Assoc. J., 173 (10) (2005), pp. 1191-1202
[12] Neumann, J.; Sö rensen, N.; Schwemer, T.; et al. JAMA Cardiology 2016, 1, 397−404.
[13] Amitava Dasgupta PhD, DABCC, Amer Wahed MD, in Clinical Chemistry, Immunology and Laboratory Quality Control, 2014
[14] Biochemistry (Moscow), Vol. 64, No. 9, 1999, pp. 969-985. Translated from Biokhimiya, Vol. 64, No. 9, 1999, pp. 1155-1174
[15] Penttilä, K., Penttilä, I., Bonnell, R., et al. (2009). Comparison of the Troponin T and Troponin I ELISA Tests, as Measured by Microplate Immunoassay Techniques, in Diagnosing Acute Myocardial Infarction. Clinical Chemistry and Laboratory Medicine, 35(10), pp. 767-774. Retrieved 21 Nov. 2018, from doi: 10.1515/cclm.1997.35.10.767
[16] Guo, Huishi; Di Yang, .; Gu, Chunrong; Bian, Zhiping, et al. Journal of Nanoscience and Nanotechnology, Volume 5, Number 12, December 2005, pp. 2161-2166(6)
[17] Recent Development of Cardiac Troponin I Detection
Xu Han, Shanghao Li, Zhili Peng, Abdelhameed M. Othman, and Roger Leblanc
ACS Sensors 2016 1 (2), 106-114
DOI: 10.1021/acssensors.5b00318
[18] Indu Sarangadharana, Abiral Regmia, Yen-Wen Chena., et al. Biosensors and Bioelectronics, Volume 100, 15 February 2018, Pages 282-289
[19] Tate, J.B., J., Bunk, D, 2012. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer.
[20] 2017. Cardiac Troponin I Booklet of Hytest.
[21] J Bausells, J Carrabina, A Errachid, A Merlos. “Sensors and Actuators B: Chemical”, Volume 57, Issues 1–3, 7 September 1999, Pages 56-62
[22] P.Bergveld, “Sensors and Actuators B: Chemical”, Volume 88, Issue 1, 1 January 2003, Pages 1-20
[23] Yi Cui1, Charles M. Lieber. “Science”, 02 Feb 2001, Vol. 291, Issue 5505, pp. 851-853, DOI: 10.1126/science.291.5505.851
[24] I. Higgins and C. Lowe, "Introduction to the principles and applications of biosensors," Philosophical Transactions of the Royal Society of London B: Biological Sciences, vol. 316, pp. 3-11, 1987.
[25] Schöning, Michael J.; Poghossian, Arshak (2002). "Recent advances in biologically sensitive field-effect transistors (BioFETs)". The Analyst. 127 (9): 1137–1151. doi:10.1039/B204444G. ISSN 0003-2654.
[26] Indu Sarangadharan, Shin-Li Wang, Tse-Yu Tai, Anil Kumar, Pulikkathodi, Chen-Pin Hsu, Hui-Hua, Kenny Chiang, Lawrence, Yu-Min Liu, Yu-Lin Wang. Biosensors and Bioelectronics, Volume 107, 1 June 2018, Pages 259-265
[27] C. H. Chu et al., Scientific Reports, 7, 5256 (2017).
[28] E. Stern et al., Nano letters, 7, 3405 (2007).
[29] Allen, B. L.; Kichambare, P. D.; Star, A. Adv. Mater. 2007, 19, 1439−1451.
[30] 陳坤明，電子元件的雜訊從何而來，奈米通訊 23卷NO.4, pp 33-34.
[31] 張劍青、張冠群等人，積體電路元件雜訊量測技術原理及其可靠度上之應用，Vol. 176, 1993, pp.33-45
[32] Han-Chou Liao, Novel Calibration and Compesation Technique, 2004.
[33] Ian Poole, What is a MOSFET: Basics & Tutorial.
[34] K. K. Hung, P. K. Ko, C. Hu, et al. “ A physic-based MOSFET noise model for circuit simulators”, IEEE Transactions on Electron Devices, Vol. 37, Issue 5, 1990, pp. 1965-1971.
[35]S.K. Arya, S. Saha, J.E. Ramirez-Vick, V. Gupta, S. Bhansali, S.P. Singh.“Recent advances in ZnO nanostructures and thin films for biosensor applications: review”, Anal. Chim. Acta, 737 (2012), pp. 1-21.
[36] A. Choi, K. Kim, H.-I. Jung, S.Y. Lee. “ZnO nanowire biosensors for detection of biomolecular interactions in enhancement mode”, Sens. Actuators B Chem., 148 (2010), pp. 577-582.
[37] Rosaria AnnaPicca, KyriakiManoli, AntonioLuciano, Maria ChiaraSportelli, GerardoPalazzo, LuisaTorsi, NicolaCioffi. “Sensors and Actuators B: Chemical”, Volume 274, 20 November 2018, Pages 210-217.
[38] Rafiq Ahmad, Nirmalya Tripathy, Yoon-Bong Hahn. “Sensors and Actuators B: Chemical”, Volume 194, April 2014, Pages 290-295
[39] Suresh Regonda, Ru hai Tian, Jin ming Gao, Serena Greene, Jia huan Ding, Walter Hu. “Biosensors and Bioelectronics”, Volume 45, 15 July 2013, Pages 245-251
[40] Karel Hernandez, Roberto Fernandez-Lafuente. “Enzyme and Microbial Technology”, Volume 48, Issue 2, 8 February 2011, Pages 107-122
[41] Kihyun Kim, Chanoh Park, Donghoon Kwon, Donghoon Kim, M.Meyyappan, Sangmin Jeon, Jeong-SooLee. Biosensors and Bioelectronics, Volume 77, 15 March 2016, Pages 695-701